Selective targeting and degradation of doxorubicin-loaded folate-functionalized DNA nanocages

Nanomedicine. 2018 Jun;14(4):1181-1190. doi: 10.1016/j.nano.2018.02.002. Epub 2018 Feb 17.

Abstract

Selective targeting is a crucial property of nanocarriers used for drug delivery in cancer therapy. We generated biotinylated octahedral DNA nanocages functionalized with folic acid through bio-orthogonal conjugation chemistry. Molecular modelling indicated that a distance of about 2.5 nm between folic acid and DNA nanocage avoids steric hindrance with the folate receptor. HeLa cells, a folate receptor positive tumour cell line, internalize folate-DNA nanocages with efficiency greater than 40 times compared to cells not expressing the folate receptors. Functionalized DNA nanocages are highly stable, not cytotoxic and can be efficiently loaded with the chemotherapeutic agent doxorubicin. After entry into cells, doxorubicin-loaded nanoparticles are confined in vesicular structures, indicating that DNA nanocages traffic through the endocytic pathway. Doxorubicin release from loaded DNA cages, facilitated by low pH of endocytic vesicles, induces toxic pathways that, besides selectively killing folate receptor-positive cancer cells, leads to cage degradation avoiding nanoparticles accumulation inside cells.

Keywords: DNA nanotechnology; Doxorubicin; Drug delivery; Folate-functionalized nanostructure; Selective targeting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Survival / drug effects
  • DNA / chemistry*
  • DNA Adducts / chemistry*
  • DNA Adducts / pharmacology
  • Doxorubicin / chemistry*
  • Doxorubicin / pharmacology
  • Drug Delivery Systems / methods*
  • Folic Acid / chemistry*
  • HT29 Cells
  • HeLa Cells
  • Humans
  • Nanoparticles / chemistry*

Substances

  • DNA Adducts
  • doxorubicin-DNA
  • Doxorubicin
  • DNA
  • Folic Acid